Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria
Sponsor: Attikon Hospital
Summary
Patients with Type 2 Diabetes Mellitus and albuminuria will be randomised eitheer to dulaglutide and dapagliflozin combination or DPP-4 inhibitor, as an add-on treatment to metformin. Arterial stiffness, UACR, endothelial glycocalyx and global longitudinal strain will be assesed at baseline, 4 and 12 months.
Official title: Study of Endothelial Glycocalyx and Vascular Function in Patients With Type 2 Diabetes and Albuminuria After Administration of Dulaglutide and Dapagliflozin vs DPP-4 Inhibitors
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2018-02-01
Completion Date
2024-12-15
Last Updated
2024-09-25
Healthy Volunteers
No
Interventions
Dulaglutide
Combined treatment with dulaglutide and dapagliflozin
DPP-4 Inhibitors
DPP-4i treatment as an add-on to metformin
Locations (1)
Attikon University General Hospital
Chaïdári, Attica, Greece